Royalty Pharma Acquires Lexiscan® and Cubicin® Royalties for $487 Million

New York, NY – April 4, 2011 – Royalty Pharma announced today that it has acquired the rights to certain royalties payable on sales of Lexiscan® and Cubicin® from an undisclosed seller for a cash payment of $487 million.

Source: Original Article